Colangiocarcinoma

Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289.Texto completo  Resumo

Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.Texto completo  Resumo

Khan SA, Davidson BR, Goldin RD, et al; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012 Dec;61(12):1657-69.Texto completo  Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: biliary tract cancers [internet publication].Texto completo

Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Apr 20;37(12):1015-1027.Texto completo  Resumo

1. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289.Texto completo  Resumo

2. Amin MB, Edge S, Greene F, et al. (eds); American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.

3. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45:856-867. Resumo

4. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171-190. Resumo

5. Levin B. Gallbladder carcinoma. Ann Oncol. 1999;10(suppl 4):129-130. Resumo

6. Pitt HA, Dooley WC, Yeo CJ, et al. Malignancies of the biliary tree. Curr Probl Surg. 1995;32:1-90. Resumo

7. Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.Texto completo  Resumo

8. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019 May;39(Suppl 1):19-31.Texto completo  Resumo

9. Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol. 1996;25:933-940. Resumo

10. Wiseman K, Buczowski AK, Chung SW, et al. Epidemiology, presentation, diagnosis, and outcomes of choledochal cysts in adults in an urban environment. Am J Surg. 2005;189:527-531. Resumo

11. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10 Suppl 4:308-311. Resumo

12. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007;120:638-641. Resumo

13. Shaib YH, El Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620-626. Resumo

14. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis. 2006;26:42-51. Resumo

15. Brown DP. Mortality of workers exposed to polychlorinated biphenyls - an update. Arch Environ Health. 1987;42:333-339. Resumo

16. Lowenfels AB, Norman J. Isoniazid and bile duct cancer. JAMA. 1978;240:434-435. Resumo

17. Yen S, Hsieh CC, Macmahon B. Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use. Cancer. 1987;59:2112-2116. Resumo

18. Rubel LR, Ishak KG. Thorotrast-associated cholangiocarcinoma: an epidemiologic and clinicopathologic study. Cancer. 1982;50:1408-1415. Resumo

19. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am. 2002;11:995-1009. Resumo

20. Tanaka K, Nishimura A, Yamada K, et al. Cancer of the gallbladder associated with anomalous junction of the pancreatobiliary duct system without bile duct dilatation. Br J Surg. 1993;80:622-624. Resumo

21. Khan SA, Davidson BR, Goldin RD, et al; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012 Dec;61(12):1657-69.Texto completo  Resumo

22. Ahrendt SA, Pitt HA, Nakeeb A, et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg. 1999;3:357-367. Resumo

23. Shaib YH, El Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102:1016-1021. Resumo

24. Wilcox CM, Monkemuller KE. Hepatobiliary diseases in patients with AIDS: focus on AIDS cholangiopathy and gallbladder disease. Dig Dis. 1998;16:205-213. Resumo

25. Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001;12:959-964. Resumo

26. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88:2471-2477. Resumo

27. Bergquist A, Glaumann H, Persson B, et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case control study. Hepatology. 1998;27:311-316. Resumo

28. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004;66:167-179. Resumo

29. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317-323. Resumo

30. Teefey SA, Hildeboldt CC, Dehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology. 2003;226:533-542. Resumo

31. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: biliary tract cancers [internet publication].Texto completo

32. Vanderveen KA, Hussain HK. Magnetic resonance imaging of cholangiocarcinoma. Cancer Imaging. 2004;4:104-115.Texto completo  Resumo

33. Fujii-Lau LL, Thosani NC, Al-Haddad M, et al. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology: summary and recommendations. Gastrointest Endosc. 2023 Nov;98(5):685-93.Texto completo  Resumo

34. ASGE Standards of Practice Committee, Coelho-Prabhu N, Forbes N, et al. Adverse events associated with EGD and EGD-related techniques. Gastrointest Endosc. 2022 Sep;96(3):389-401.e1.Texto completo  Resumo

35. Lan BY, Kwee SA, Wong LL. Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. Am J Surg. 2012;204:232-241. Resumo

36. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg. 1995;130:270-276. Resumo

37. Alvaro D, Bragazzi MC, Benedetti A, et al. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. Dig Liver Dis. 2011;43(1):60-5. Resumo

38. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000 Jan;95(1):204-7. Resumo

39. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31:7-11. Resumo

40. Farrell RJ, Agarwal B, Brandwein SL, et al. Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc. 2002;56:681-687. Resumo

41. Yamashita Y, Takahashi M, Kanazawa S, et al. Parenchymal changes of the liver in cholangiocarcinoma: CT evaluation. Gastrointest Radiol. 1992;17:161-166. Resumo

42. Magnuson TH, Bender JS, Duncan MD, et al. Utility of magnetic resonance cholangiography in the evaluation of biliary obstruction. J Am Coll Surg. 1999;189:63-71. Resumo

43. Wiersema MJ, Vilmann P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology. 1997;112:1087-1095. Resumo

44. Allen VB, Gurusamy KS, Takwoingi Y, et al. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016 Jul 6;7:CD009323. Resumo

45. Yeh CN, Jan YY, Yeh TS, et al. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol. 2004;11:606-611. Resumo

46. Nakagohri T, Asano T, Kinoshita H, et al. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg. 2003;27:289-293. Resumo

47. Isaji S, Kawarada Y, Taoka H, et al. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6:108-116. Resumo

48. Berdah SV, Delpero JR, Garcia S, et al. A western surgical experience of peripheral cholangiocarcinoma. Br J Surg. 1996;83:1517-1521. Resumo

49. Chen Y, Zhang B, Liu C, et al. Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. BMJ Open. 2022 Apr 19;12(4):e051421.Texto completo  Resumo

50. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: biliary tract cancers [internet publication].Texto completo

51. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May;20(5):663-73. Resumo

52. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Apr 20;37(12):1015-1027.Texto completo  Resumo

53. Oh DY, Aiwu RH, Qin S, et al. ​Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022 Jun 1;1(8).Texto completo

54. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.Texto completo  Resumo

55. Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022 Jan-Feb;12(1):28-51.Texto completo  Resumo

56. Nimura Y, Hayakawa N, Kamiya J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg. 1990;14:535-544. Resumo

57. Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford). 2013;15:492-503. Resumo

58. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391-398. Resumo

59. Yang R, Wang B, Chen YJ, et al. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. Anticancer Drugs. 2013;24:871-877. Resumo

60. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107:521-527. Resumo

61. Nagino M, Nimura Y, Kamiya J, et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology. 1995;21:434-439. Resumo

62. Liu F, Li Y, Wei Y, et al. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Digest Dis Sci. 2011;56:663-672. Resumo

63. Celotti A, Solaini L, Montori G, et al. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur J Surg Oncol. 2017 Sep;43(9):1628-35. Resumo

64. Fang Y, Gurusamy KS, Wang Q, et al. Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg. 2013 Nov;100(12):1589-96. Resumo

65. Mumtaz K, Hamid S, Jafri W. Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgery. Cochrane Database Syst Rev. 2007;(3):CD006001. Resumo

66. Dumonceau JM, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. Endoscopy. 2018 Sep;50(9):910-930.Texto completo  Resumo

67. Elmunzer BJ, Maranki JL, Gómez V, et al. ACG Clinical guideline: diagnosis and management of Biliary Strictures. Am J Gastroenterol. 2023 Mar 1;118(3):405-26.Texto completo  Resumo

68. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507-519.Texto completo  Resumo

69. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma, Am J Transplant. 2002;2:774-779. Resumo

70. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201-207. Resumo

71. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451-461.Texto completo  Resumo

72. Heimbach JK, Haddock MG, Alberts SR, et al. Transplantation for hilar cholangiocarcinoma. Liver Transpl. 2004;10(10 suppl 2):S65-S68. Resumo

73. Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 May;22(5):690-701.Texto completo  Resumo

74. Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 1999;44:121-126. Resumo

75. Ray CE Jr, Edwards A, Smith MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013;24:1218-1226.Texto completo  Resumo

76. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119-2128.Texto completo  Resumo

77. National Institute for Health and Care Excellence. Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma. Oct 2018 [internet publication].Texto completo

78. ClinicalTrials.gov. Gemcitabine and cisplatin with or without CPI-613 as first line therapy for patients with advanced unresectable biliary tract cancer (BilT-04). ClinicalTrials.gov Identifier: NCT04203160. Jun 2021 [internet publication].Texto completo

79. Pape U‐F, Kasper S, Meiler J, et al. Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC). J Clin Oncol. 2019 Feb 1;37(4 suppl):264Texto completo

80. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-15.Texto completo  Resumo

81. ClinicalTrials.gov. A study of TAS-120 in patients with advanced solid tumors. ClinicalTrials.gov Identifier: NCT02052778. Jan 2022 [internet publication].Texto completo

82. ClinicalTrials.gov. Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3). ClinicalTrials.gov Identifier: NCT04093362. Jan 2022 [internet publication].Texto completo

83. Guo Y, Yuan C, Ying J, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. J Clin Oncol. 2021 May 20;39(15 suppl):4092.Texto completo

84. Correction to Lancet Oncol 2020; 21: 796-807. Lancet Oncol. 2020 Oct;21(10):e462.Texto completo  Resumo

85. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021 Nov 1;7(11):1669-77.Texto completo  Resumo

86. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671-84. Resumo

87. National Institute for Health and Care Excellence: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. Aug 2022 [internet publication].Texto completo

88. ClinicalTrials.gov. A study of ZW25 (zanidatamab) in subjects with advanced or metastatic HER2-amplified biliary tract cancers (HERIZON-BTC-01). ClinicalTrials.gov Identifier: NCT04466891. Dec 2021 [internet publication].Texto completo

89. Borad M, Bai L, Chen M, et al. Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: a phase Ib/II study. J Clin Oncol. 2021 Jan 20;39(3 suppl):312.

90. ​ClinicalTrials.gov. A phase 1/2, first-in-Human, open label, dose escalation study of a CSP targeting functional antibody in solid tumors. Oct 2021 [internet publication].Texto completo

91. Furuse J, Okusaka T, Funakoshi A, et al. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol. 2006;36:552-556. Resumo

92. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma results in 207 patients. Transplantation. 2000;69:1633-1637. Resumo

93. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Resumo

94. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].Texto completo